ProCE Banner Activity

Niraparib in Patients with BRCA-Mutated Ovarian Cancer: Analysis of 3 Phase III Trials

Slideset Download
Conference Coverage
Data from 3 phase III studies confirm efficacy of niraparib maintenance treatment in patients with BRCAm ovarian cancer following platinum-based chemotherapy in first-line and recurrent disease settings.

Released: June 07, 2021

Expiration: June 06, 2022

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis

Gilead Sciences, Inc.

GlaxoSmithKline

Ipsen Biopharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Pfizer, Inc.

Pharmacyclics LLC an AbbVie Company and Janssen Biotech Inc

Sanofi Genzyme